Bayer Starts Phase III Study Of Riociguat
Edited Press Release FRANKFURT -(Dow Jones)- German pharmaceutical maker Bayer AG (BAY.XE) said Monday its Bayer Schering Pharma unit has begun phase III program trials with the oral pulmonary agent riociguat.
Two phase III trials will investigate the application in patients with both chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).